NCT06081673View on ClinicalTrials.gov

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

October 30, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Penpulimab injection

Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).

DRUG

cisplatin

Cisplatin :75mg/m2, D1, IV(21 days/cycle)

DRUG

albumin-paclitaxel

albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER